Novo Nordisk A/s

Brit Binow Soerensen

Ida Hilden

Jes Thorn Clausen

Ole Hvilsted Olsen

Jens Breinholt

Lars Christian Petersen

Berit Olsen Krogh

Helle Heibroch Petersen

Brian Lauritzen

Anders Svensson

The invention relates to antibodies that specifically bind to tissue factor pathway inhibitor (TFPI) and that reduce the clotting time of blood. Such antibodies have utility in the treatment of subjects with a coagulopathy.

Antibodies against tissue factor pathway inhibitor

The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralising free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.

Antibodies that are capable of specifically binding tissue factor pathway inhibitor

The invention relates to antibodies that are capable of specifically binding tissue factor pathway inhibitor (TFPI), neutralizing free TFPI and reducing the clotting time of blood. Furthermore, the invention relates to polynucleotides that encode such antibodies and to cells that comprise the polynucleotides or that express the antibodies of the invention. Such antibodies have utility in the treatment of subjects with a coagulopathy, alone as well as in combination with a second agent.

Methods of treating coagulopathies using antibodies against tissue factor pathway inhibitor

Growing community of inventors

Birkeroed, Denmark

Brit Binow Soerensen